Parc d’Innovation d’Illkirch, France, March 10, 2010 – Transgene S.A. (Euronext Paris: FR0005175080) announced the signing of an exclusive option agreement with Novartis for the development and commercialisation of Transgene’s targeted immunotherapy product, TG4010 (MVA-MUC1-IL2), for the first-line treatment of non-small cell lung cancer (NSCLC) and other potential cancer indications.Pursuant to the agreement, Transgene has granted Novartis an option to acquire an exclusive worldwide license for TG4010 and Novartis will pay Transgene a $10 million non-refundable option fee. Contingent upon the exercise of the option by Novartis and the achievement of successful development, regulatory and commercial milestones in various indications, Transgene is eligible to receive up to a total of approximately €700 million.
According to the agreement, Transgene will initially fund and retain control over the next clinical development phase of TG4010, which is a pivotal, global phase IIb/III clinical trial that Transgene currently anticipates starting by the end of 2010. This study will involve approximately 1,000 patients with MUC1-positive NSCLC who have normal levels of activated Natural Killer (NK) cells at time of trial entry1. The final results are expected to become available by the end of 2013...
[...]
...About Transgene
Transgene is a France-based biopharmaceutical company dedicated to the development of
therapeutic vaccines and immunotherapeutic products in oncology and infectious diseases.
The company has three compounds in phase II trials (TG4001/R3484, TG4010 and TG1042)
and two compounds in phase I studies (TG4040 and TG4023)... [PDF] Transgene's Press Release - PDF du communiqué de presse de Transgene -
